Cencora (WBO:ABC) Moat Score: 5/10 (As of Jun. 27, 2026)


WBO:ABC Cencora Inc WBO:ABC
69 GF Score
Price €254.30
GF Value €259.48
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Cencora Moat Score?

Cencora WBO:ABC -0.27% 69 Moat Score is 5 as of Jun. 27, 2026. GuruFocus rates WBO:ABC with a GF Score™ of 69/100 and a GF Value™ of €259.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 121 Medical Distribution companies, Cencora ranks better than 92.56% on this metric.

Cencora has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Cencora has Narrow Moat: Cencora Inc benefits from a solid distribution network and some customer loyalty. However, it lacks the significant regulatory barriers or exclusive licenses needed for a wide moat, making its competitive advantages modest.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cencora might have Narrow Moat - Solid narrow moat.

Cencora  (WBO:ABC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cencora Moat Score Related Terms

WBO:ABC vs CAH, MCK, HSIC: Moat Score Comparison

For the Medical Distribution subindustry, Cencora's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cencora Moat Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cencora's Moat Score distribution charts can be found below:

* The bar in red indicates where Cencora's Moat Score falls into.


WBO:ABC
69GF Score
Cencora Inc WBO:ABC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Cencora (WBO:ABC) has a Moat Score of 5 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cencora ranks #9 out of 121 companies in the Medical Distribution industry, placing it in the top 7.4%.
Is Cencora's Moat Score too high?
Cencora's current Moat Score is 5. Based on the distribution chart, Cencora ranks #9 out of 121 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cencora has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's Moat Score compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #9 out of 121 companies for Moat Score. This places Cencora in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Distribution company?
A good Moat Score depends on the Medical Distribution industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Cencora's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €259.48, compared to a current price of €254.30 — trading 2% below its estimated fair value. The current Moat Score is 5. Cencora's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cencora (WBO:ABC), the current Moat Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cencora (WBO:ABC) Overvalued in 2026?

Based on GuruFocus' analysis, Cencora stock appears to be undervalued. The current stock price of €254.30 is trading 2% below its estimated GF Value™ of €259.48. GuruFocus considers Cencora to be Fairly Valued.

Key valuation signals for WBO:ABC:

  • Moat Score: 5
  • GF Value™: €259.48 vs. price of €254.30 (2% below fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cencora Business Description

Address 1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
69GF Score

Get the complete analysis for WBO:ABC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€254.30
Price
€259.48
GF Value